Atom Investors’s Vertex Pharmaceuticals VRTX Stock Holding History

Atom Investors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-7,109	Closed	-$2.78M	–	823
2025 Q3	$2.78M	Buy	7,109 +6,139	+633%	+$2.57M	0.21%	135
2025 Q2	$432K	Buy	+970	New	+$447K	0.04%	372
2023 Q4	–	Sell	-2,760	Closed	-$960K	–	556
2023 Q3	$960K	Buy	2,760 +2,041	+284%	+$714K	0.22%	143
2023 Q2	$253K	Buy	719 +13	+2%	+$4.38K	0.1%	210
2023 Q1	$222K	Buy	+706	New	+$212K	0.12%	192
2022 Q2	–	Sell	-2,201	Closed	-$574K	–	315
2022 Q1	$574K	Buy	+2,201	New	+$522K	0.27%	90

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Atom Investors's VRTX Position: Q4 2025 in Review

Atom Investors sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 7,109 shares — an estimated $2.78M sold.

Atom Investors first reported a position in VRTX in Q1 2022 and held it in 6 quarters. The position peaked at $2.78M in Q3 2025. 1,668 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

Atom Investors reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Atom Investors sold 7,109 Vertex Pharmaceuticals shares in Q4 2025, an estimated $2.78M.
Atom Investors first reported a position in Vertex Pharmaceuticals in Q1 2022 and held it in 6 quarters.
Atom Investors's Vertex Pharmaceuticals position peaked at $2.78M in Q3 2025.
1,668 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Atom Investors's 13F filing for Q4 2025, filed 17 Feb 2026.